Pharmacy and Biopharmacy Policies To Be Updated As of June 1st
Effective June 1, 2022: Pharmacy and Biopharmacy Policies
Superior HealthPlan has updated certain pharmacy and biopharmacy policies to ensure medical necessity review criteria is current and appropriate for members and the scope of services provided. As a result the following policies are effective on June 1, 2022, at 12:00AM.
Pembrolizumab (Keytruda) (CP.PHAR.322)
Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP, and Ambetter
New Policy Overview Or Updated Policy Revisions
Policy updates include:
Removal of previously approved indication for usage as third-line monotherapy for PD-L1 positive gastric/GEJ cancer patients per updated prescribing information